Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Compatibility of Nivestim Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases

Trial Profile

The Compatibility of Nivestim Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary) ; Filgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VENICE
  • Sponsors Hospira
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Oct 2016 Results published in the Advances in Therapy
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top